knowledge -WSS

knowledge

author：explore 2025-09-30 16:29:05 - browse：8974

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

WSS

These geoengineering technologies could help combat the climate crisis, scientists say

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

7 people shot in DC, police say

PBM reform efforts get punted in Congress

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

NIH study of ME/CFS points to clear biological hallmarks

explore

knowledge

A Worst CEO gets some much-needed help

leisure time

Medical leaders decry Supreme Court decision on affirmative action

PBM reform efforts get punted in Congress

Wildfire smoke exposes gaps in outdoor worker protections

Australia's humpback populations rebound raising hopes of marine scientists

Wildfire smoke exposes gaps in outdoor worker protections

Antivenom research: Lessons from HIV applied in search for universal antidote

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Hepatitis C has a cure — but many Americans still lack access to it

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

hotspot

Why palliative psychiatry is worth discussing

New case study details death in closely watched Alzhiemer's trial

Inside the fall of star MIT scientist David Sabatini

Make 'food is medicine' a key part of White House nutrition meeting

Pfizer's Covid pill remains 89% effective in final analysis, company says

7 people shot in DC, police say

focus

knowledge

hotspot

explore